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Abstract
Mycobacterium bovis is the causative agent of tuberculosis in cattle but also infects other animals, including humans.
Previous studies in cattle have demonstrated that the protection induced by BCG is not complete. In order to improve the
protection efficacy of BCG, in this study we overexpressed Ag85B in a BCG Pasteur strain, by using an expression system
based on the use of an auxotrophic strain for the leucine amino acid, and complementation with leuD. We found that
vaccination of cattle with BCG overexpressing Ag85B induced higher production of IL-17 and IL-4 mRNA upon purified
protein derivative (PPDB) stimulation of peripheral blood mononuclear cells (PBMCs) than vaccination with BCG. Moreover,
the IL-17 mRNA expression after vaccination negatively correlated with disease severity resulting from a subsequent
challenge with M. bovis, suggesting that this cytokine is a potential biomarker of cattle protection against bovine
tuberculosis. Importantly, vaccination with the recombinant BCG vaccine protected cattle better than the wild-type BCG
Pasteur.
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Introduction
Bovine tuberculosis (bTB) is not only a serious animal and
zoonotic disease that causes significant financial loss but also a
public health hazard. While the main host of Mycobacterium bovis,
the causative agent of bTB, is cattle, other animals, including
humans, may also be affected. Infection in humans occurs when
unpasteurized milk (or derivatives) is consumed or when people
are in contact with infected cattle. bTB is a factor that undermines
the development of the dairy and meat industry and international
commerce. Therefore, it is essential to control and eradicate this
disease and an efficient vaccination strategy would help in the
control of bTB. Vaccination of cattle to control bTB is particularly
demanding in high-prevalence zones where it is economically
unfeasible to slaughter animals [1].
Although previous studies with BCG in cattle have demonstrat-
ed reductions in disease severity after experimental challenge with
virulent M. bovis strains, the protection induced by BCG was, in
general, not complete [2–4]. The heterologous prime-boost
strategy has shown to be the most promising approach to protect
cattle against M. bovis challenge, and the combinations of BCG–
DNA [5–7], BCG–protein [8,9] and BCG–virus vectored vaccines
[10] have been shown to induce better protection than BCG
alone. However, some of these vaccination schemes demand an
expensive production of booster vaccines and require additional
handling of herds than single-dose vaccination schemes. The latter
is particularly important in extensive breeding herds. In this study,
we explored the attractive alternative of improving the protective
efficacy of the BCG vaccine. To this purpose, we created a
recombinant BCG strain that overexpresses Ag85B. The 85B
antigen is a member of a protein complex commonly known as the
Fbp complex (Ag85), which includes Ag85A, Ag85B and Ag85C
[11]. These proteins are encoded by the fbpA, fbpB and fbpC2
genes, which are located in different genomic regions. The Fbp
complex is the main secreted protein constituent of mycobacterial
cell culture and is also found in association with the bacterial
surface [11,12]. These proteins play an essential role in the
pathogenesis of tuberculosis, and their main contribution to the
virulence of M. tuberculosis is due to their physiological role in the
synthesis of cell wall lipids [13,14]. Both Ag85A and Ag85B have
been shown to be among the most potent antigens identified
[15,16]. When expressed in a variety of delivery systems, these
antigens have been shown to significantly improve the protection
conferred by candidate vaccines against tuberculosis in animal
models [17]. In this study, we overexpressed Ag85B in a BCG
Pasteur strain, by using an expression system based on the use of a
auxotrophic strain for the leucine amino acid, and complemen-
tation with leuD inserted into the plasmid vector (pUP410) [18].
This approach has two main advantages: it provides active
selection in vivo, unlike antibiotic resistance markers, and it
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abolishes the need for using an antibiotic resistance gene as a
vector component [18]. The protection efficacy of the resulting
DleuD BCG-85B candidate vaccine against M. bovis challenge as
well as the immune responses induced by the vaccine were tested
in cattle and the results were compared with those obtained with
BCG vaccination. We demonstrated that the recombinant BCG
vaccine protects cattle better than the wild-type BCG Pasteur.
Materials and Methods
Ethics Statement
Animal experimentations were performed inside the biosafety
facilities of the National Institute of Agricultural Technology
(INTA), Argentina, in compliance with the regulations of
Institutional Animal Care and Use Committee (CICUAE) of
INTA and authorized by the National Service of Agricultural and
Food Health and Quality (SENASA) and National Consultant
Commission of Agricultural Biotechnology (CONABIA). Ethical
approval for the study was obtained from CICUAE (nu 18/2011).
Bacterial Strains and Culture Media
Mycobacterium bovis BCG strains were grown in Middlebrook
7H9 medium supplemented with 0.05% Tween 80 or in
Middlebrook 7H10. Middlebrook media were supplemented with
oleic acid-albumin-dextrose-catalase (OADC - Difco), 0.05% of
Tween 80 and 0.2% of glycerol. When required, the L-leucine
(Sigma-Aldrich, St. Louis, Missouri, USA) was added to a final
concentration of 100 mg/ml. The Escherichia coli strain TOP10
(Invitrogen, Carlsbad, CA, USA) was used for cloning and was
grown in Luria-Bertani medium at 37uC with addition of
kanamycin 50 mg/ml.
Cloning of the fbpB Gene and Construction of BCG DleuD
Expressing Ag85B
The coding sequences for the Ag85B antigen were amplified
from the fbpB gene of M. bovis genomic DNA. Primers used for
fbpB gene PCR amplification were based on the complete M. bovis
AF2122/97 genome sequence (59-GGGGTACCCGCTATG-
TAGCTCCAATTC-39 and 59- GGGGTACCT-
CAGCCGGCGCC-39), and were designed using Vector NTI
10.0 (Invitrogen, Carlsbad, CA, USA). Both forward and reverse
primers contain restriction sites for KpnI. The M. bovis 30-kDa
antigen gene cassette, consisting of the fbpB gene coding region
and its endogenous promoter (1500 bp), were obtained using
standard PCR conditions and the enzyme Go TaqH Hot Start
Polymerase Sample (Promega, Madison, Wiscosin, USA). The
PCR product was digested with the KpnI enzyme (Promega,
Madison, Wiscosin, USA), and inserted into the pUP410 vector,
which had been previously digested with the same restriction
enzyme. Competent E. coli was then transformed with the
recombinant plasmid (pUP410::fbpB) and the clones were checked
by restriction enzyme digestion and PCR. To remove the
kanamycin resistance gene by digestion, pUP410::fbpB was
digested with HindIII and re-ligated with T4 DNA ligase
(Invitrogen, Carlsbad, CA, USA).
Mycobacterium bovis BCG Pasteur DleuD electrocompetent cells
were transformed with the product of ligation (pUP410::fbpB
DkanR) and recombinant strains were selected in 7H10 media
without L- leucine. Recombinant BCG were grown for 5 days in
selective 7H9 media, the cells were harvested by centrifugation,
and the total proteins were obtained by disruption using a
ribolyser (Hybaid, Kalletal, Germany). The filtered culture
supernatant was concentrated by precipitation with saturated
ammonium sulfate solution. Proteins were fractionated on sodium
dodecyl sulphate (SDS) 215% polyacrylamide gel and transferred
to nitrocellulose membrane (GE Healthcare Live Sciences, Little
Chalfont, Buckinghamshire, UK). Blots were probed with a mouse
polyclonal antibody anti-Ag85B. Peroxidase-conjugated anti-
mouse immunoglobulin G (Sigma-Aldrich, St. Louis, Missouri,
USA) was used at a dilution of 1:6000. Detection was carried out
using TMB Liquid Substrate System (Sigma-Aldrich, St. Louis,
Missouri, USA).
Cattle Infections
All the animals used in this study were negative for the
tuberculin skin test and showed absence of in vitro gamma
interferon (IFN-c) response to both avian tuberculin PPD (PPDA)
and bovine tuberculin PPD (PPDB) at the beginning of the
experiments. The results shown in this study are part of a trial that
included another candidate vaccine whose results will be
separately published.
Three groups of five-six Holstein-Fresian calves (three-four
months old) were inoculated subcutaneously in the side of the neck
with 106 colony forming units (CFU) of either DleuD BCG-85B
Pasteur, or BCG Pasteur suspended in buffer phosphate saline
(PBS) or PBS. Eight weeks after vaccination, animals were infected
with a wild boar strain M. bovis 04-303 by intratracheal instillation
of 106 CFU as described previously [19]. This inoculation
procedure was carried out by first anaesthetizing the calves with
xylazine HCl (Rompun, Bayer, Germany; 0.1 mg/kg) intrave-
nously and then inserting an 80 cm endotracheal tube into
trachea. A cannula was inserted through the endotracheal tube.
The 1.5 ml inoculum containing the M. bovis was injected through
the cannula and flushed out with sterile saline equal to 1.5 times
the volume of the dead space of the cannula.
Post-mortem Examination
Sixteen weeks after infection, the calves were euthanized and
then thin slices of lungs and lymph nodes of the head and
pulmonary region were analysed looking for granuloma forma-
tions. Animals that presented macroscopic lesions were positive for
either bacterial isolation, IS6110-PCR in tissues or both.
Macroscopic lesions were scored as following: Lung lesion scores:
0, no lesions; 1, 1 to 9 lesions; 2, 10 to 29 lesions; 3, 30 to 99
lesions; 4, 100 to 199 lesions; 5, $200 lesions. Total lymph node
lesion score per animal for individual nodes: 0, no lesions; 1, 1 to
19 small lesions (diameter, 1 to 4 mm); 2, $20 small lesions; 3,
medium-size lesions (diameter, 5 to 9 mm); 4, large lesions
(diameter, $10 mm). Theses scores have been previously estab-
lished by Wedlock et al. [20].
Tissues were fixed in 10% formal saline and processed for
histological examination following staining with hematoxylin and
eosin. Histophathological lesions were scored as following: score 0:
without pathological changes; score 1: pneumonia and peribron-
chial infiltration; score 2: most of granuloma type I; score 3:
granuloma type I and II; score 4: most of granuloma type II, score
5: granulome type II and III; score 6: most of granuloma type III;
score 7: granuloma type III and IV; score 8: most of granuloma
type IV; score 9: granuloma type IV and cellular infiltration in
bronchioles.
Gamma Interferon (IFN-c) Release Assay
Blood samples were taken both at the beginning of the
experiment for evaluation of pre-immune status and at the
following time points: 30 and 60 days post-vaccination, and 40, 70
and 100 days post-challenge. Heparinized blood samples were
dispensed in 200 ml aliquots into individual wells of a 96-well plate.
Wells contained whole blood plus 20 mg/ml M. bovis PPDB
DleuD BCG-85B Cattle Vaccination and Challenge
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(Prionics, Shlieren, Zurich, Switzerland), 20 mg/ml Mycobacterium
avium PPDA (Prionics, Shlieren, Zurich, Switzerland). Blood
cultures were incubated for 18 h, and plasma was harvested and
stored at 280uC. IFN-c concentrations in stimulated plasma were
determined using a commercial ELISA-based kit (BovigamTM;
Prionics, Shlieren, Zurich, Switzerland). Absorbance of standards
and test samples were read at 450 nm. The optical density (OD)
for the PBS controls, which was usually approximately 0.1 OD
units, was used to normalize individual readouts and to calculate
the differential optical density indexes (ODIs), where the results
were obtained by subtracting the results of the PBS-stimulated
cultures from that for the antigen stimulated cultures were divided
by the results of the PBS-stimulated cultures.
Tuberculin Testing
All animals were tested for skin tuberculin test (DTH) both
before and one month after vaccination, and three months after
the M. bovis challenge. Animals were intradermally injected with
0.1 mg of PPDB and the thickness of the caudal fold tuberculin
skin test was measured using callipers before and 72 h after
injection. PPDB was obtained from the National Service of
Agricultural and Food Health and Quality (SENASA, Buenos
Aires, Argentina).
Flow Cytometry and Cytokine mRNA Analysis
Blood samples were taken both at the beginning of the
experiment for evaluation of the pre-immune status and at the
following time points: 15, 30 and 60 days post-vaccination, and 20,
40, 70 and 100 days post-challenge. For cytokine analysis blood
samples were taken only 15 and 30 days post-vaccination.
Heparinized blood (10 ml) from each animal was used for
PBMC isolation by gradient centrifugation over Histopaque 1077
(Sigma-Aldrich, St. Louis, Missouri, USA) following the manu-
facturer’s protocol. PBMCs were incubated at 37uC in RPMI
complete medium supplemented with 10% of bovine fetal serum
(Internegocios, Mercedes, Buenos Aires, Argentina) and 20 mg/ml
final concentration of PPDB (Prionics, Shlieren, Zurich, Switzer-
land) on 12-well tissue culture plates for 16 h for RNA extraction
and 48 h for flow cytometry determinations.
For flow cytometry determinations, 26106 cells were incubated
either with or without PPDB. To evaluate the expression of CD4
(MCA 1653A647, IgG2a), CD8 (MCA837PE, IgG2a) and CD25
(MCA2430F and MCA2430PE) surface markers, cells were
stained with fluorescent-conjugated monoclonal antibodies (Ad-
DSerotec, Oxford, UK).
Stained cells were analysed in a FACScalibur cytometer (BD,
Franklin Lakes, NJ, USA) using Cell Quest software. Analysis gates
were set on lymphocytes according to forward and side scatter.
Expression of CD25 (IL-2R) was analysed in CD4+ and CD8+
populations. Percentages of IL-2R-expressing cells were calculated
as the ratio of CD4+ or CD8+ cells expressing CD25 and total
CD4+ or CD8+ cells. Mann-Whitney test was used for statistical
analysis.
Total RNA was extracted from PPDB-stimulated PBMCs using
a commercial kit (QIAGEN). The quality and quantity of RNA
and the synthesis of cDNA were assayed as described previously
[21]. The mRNA of cytokines (IL-2, IL-4, IL-10, IL-17, and IFN-
c) was quantified by qPCR by using specific primers [21]. qPCR
results were analysed using the REST software as described
previously [22]. For each animal, the pre-immune condition was
used as the calibrator, and gadph were used as reference genes.
Data were analysed using Mann-Whitney test. Correlation
analysis between total gross pathology scores observed at necropsy
and cytokine expression of individual animals were made at 15
and 30 days post-vaccination and at 20, 40, 60 and 100 days post
challenge.
Statistical Analyses
Statistical analysis was performed using GraphPad prism 5.03
software (GraphPad Software, San Diego California USA).
Differences in pathology scores, DTH, cell activation and cytokine
transcription were analysed using Mann-Whitney non parametric
two-tailed t test. Differences in IFN-c production was analysed
using ANOVA test. Correlations between cytokine expression or
Bovigam assay and the degree of pathology were assessed by linear
regression analysis.
Results
Construction and Ag85B Overexpression of Recombinant
BCG
The integrity of the recombinant vector pUP410::fbpB used in
this study to over express Ag85B in BCG Pasteur was confirmed
by PCR and restriction site analysis (data not shown). Recombi-
nant protein was readily detectable in DleuD BCG-85B lysates and
culture supernatants by Western blot using polyclonal anti-Ag85
antibody (Figure 1). Both the cytoplasm and the secreted
recombinant protein presented 30 kDa of molecular mass, visually
in greater quantities than in wild-type BCG Pasteur, which has
relatively low levels of endogenous expression of Ag85B.
Protective Efficacy of DleuD BCG-85B
Groups of calves were vaccinated with either BCG Pasteur or
BCG Pasteur overexpressing Ag85B. A third group was left
unvaccinated. Eight weeks after vaccination, calves were chal-
lenged intratracheally with M. bovis.
The level of protection afforded by each strain of BCG was
determined at 16 weeks post-challenge. Although all groups of
animals presented typical tuberculosis lesions in lungs or lymph
nodes, the number of lesions varied between groups. Although
both vaccinated groups (DleuD BCG-85B and BCG) showed
reduced pathology in the pulmonary lymph nodes compared to
that of nonvaccinated animals, as judged by the number of
lesioned lymph nodes, this parameter did not reach statistical
significance (data not shown). In contrast, the median score for
lesions in lungs in the groups vaccinated with either DleuD BCG-
85B or BCG was statistically lower than that of the nonvaccinated
group (Figure 2A, P,0.05). Importantly, the total pathology
scores, which take into account disease severity in lungs and lymph
nodes, were significantly reduced after DleuD BCG-85B vaccina-
tion but not after BCG vaccination, when compared to those for
nonvaccinated animals (Figure 2B, P,0.05).
Figure 1. Western blot demonstrating Ag85B expression in
BCG Pasteur DleuD. Lane 1, whole-cell lysates of rBCG transformed
with pUP410::fbpB; lane 2, culture supernatant of rBCG transformed
with pUP410::fbpB; lane 3, whole-cell lysates of wild-type BCG; lane 4,
culture supernatant wild-type BCG.
doi:10.1371/journal.pone.0051396.g001
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A histopathological analysis of lung lesions revealed that both
vaccinated groups (DleuD BCG-85B and BCG) showed signifi-
cantly reduced pathology when compared to that in lungs of
nonvaccinated animals, as judged by the type of lesions. Moreover,
the median score for lesions in lungs in the groups vaccinated with
DleuD BCG-85B was statistically lower than that of the BCG-
vaccinated group (P,0.05).
In detail, the nonvaccinated group presented numerous small,
medium and large lesions in thoracic LN (Material S1). A single
animal had a large number of small and medium lesions in head
LN (data not shown). Five animals developed a variable number of
macroscopic lung lesions: from 14 small lesions to large areas of
confluent lesions, affecting whole lung lobes (Figure 2 and Material
S2). This group presented lung lesions with a high prevalence of
type IV granulomas and these were surrounded by type I
granulomas indicating the active proliferation of M. bovis and
abundant cellular infiltration in the bronchioles (Figure 3 and
Material S2). In the BCG vaccinated group only two animals
exhibited lesions in lungs (2 and 17 lesions) with sizes ranging from
2-10 mm in diameter (Figure 2 and Material S2). The lesions
contained type III granulomas, some type IV granulomas
surrounded by abundant type I granulomas and pneumonia
(Figure 3 and Material S2). All animals showed small lesions in
lung LN (6-100 lesions/LN) (Material S1). A single animal had 7
small lesions in head LN (data not shown). Finally, in the DleuD
BCG-85B-vaccinated group a single animal had one macroscopic
lung lesion of 5 mm with small type I granulomas (Figure 2, 3 and
Material S2). Four animals showed small lesions in thoracic LN
with granulomas type I, III and IV, and no lesions in head LN
were observed. Taken together, these results indicate that DleuD
BCG-85B protects cattle better than BCG, as judged by the
severity of the lesions in lungs and lymph nodes.
Blood IFN-c Responses after Vaccination and Challenge
IFN-c production after in vitro stimulation with purified protein
derivative (PPDB) was monitored in blood samples from all animal
groups at different points after vaccination and challenge. At 30
post-vaccination, only blood samples from the DleuD BCG-85B -
vaccinated group responded with significantly higher IFN-c
production (P,0.05) than that from blood samples from the
nonvaccinated group (Figure 4A). Post-challenge, all animal
groups displayed strong IFN-c responses, and no significant
differences were detected among them from this point on
(Figure 4A).
Figure 2. Protective efficacy as measured by gross pathology. The calves were euthanized sixteen weeks after infection and thin slices of
lungs and lymph nodes were analysed looking for granuloma formations. Pathology scores were established using the scoring system described in
Material and Methods (A) Mean pathology scores of lungs in vaccinated and nonvaccinated groups. (B) Mean pathology scores of total lesions (head
lymph nodes, respiratory tract-associated lymph nodes and lungs) in vaccinated and nonvaccinated groups. Pathology scores for individual animals
are plotted. Horizontal lines indicate median values. Significance was determined by Mann Whitney test: * Statistically significantly different, P,0.05.
doi:10.1371/journal.pone.0051396.g002
Figure 3. Protective efficacy as measured by histopathology in
lungs. Histopathology scores in lungs of individual animals in
vaccinated and nonvaccinated groups are plotted. Tissue samples from
lungs and lymph nodes were obtained sixteen weeks after infection.
Histopathology scores were established using the scoring system
described in Material and Methods. Horizontal lines indicate mean
values. Significance was determined by Mann Whitney test, *
Statistically significantly different, P,0.05.
doi:10.1371/journal.pone.0051396.g003
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We compared the IFN-c production in whole-blood cultures
after vaccination and challenge in relation to the pathology found
at post-mortem. We found a statistically significant positive
correlation (P=0.023) between IFN-c production upon PPDB
stimulation at 40 days post-challenge and disease severity as
judged by macroscopic analysis of lesion (scores) in lungs and
lymph nodes following challenge (Figure 4B). There was no
statistically significant correlation between IFN-c production and
disease severity in other time points assessed.
Skin Test Reactivity in Vaccinated and Nonvaccinated
Calves after Vaccination and Challenge
Skin test reactivity was evaluated after vaccination and
challenge in all cattle groups. Calves vaccinated with either
BCG or DleuD BCG-85B reacted to PPDB antigen at one month
post-vaccination, while all animals in the nonvaccinated group
were negative for this test. The mean skin thickness for the BCG
group was statistically lower than that of the DleuD BCG-85B
group (P,0.005), prior toM. bovis challenge (Figure 5A). However,
upon sacrifice (three months post challenge), only the response to
PPD in the DleuD BCG-85B group was significantly lower than in
the nonvaccinated group (Figure 5B, P,0.05). No correlation was
detected between skin test reactivity and disease severity, as judged
by scores of total lesions (data not shown).
Activation of CD4+, CD8+ in PPDB after Vaccination and
Challenge
The recall response to PPDB of lymphocyte subsets in
vaccinated and nonvaccinated animals was evaluated after
vaccination and challenge. At two week post-vaccination, the
percentages of CD4+ T and CD8+ T cells expressing CD25 in
DleuD BCG-85B -vaccinated calves peaked significantly (P,0.01
and P,0.05, respectively) upon stimulation with PPDB as
compared to those in nonvaccinated calves (Figure 6A and B).
In contrast, the mean percentages of CD4+ T and CD8+ T cells in
the BCG-vaccinated group were equivalent to those of non-
vaccinated animals. After challenge, the percentages of both
CD4+ and CD8+ T cells upon stimulation were similar in animal
groups, peaking at 70 days post-challenge. Importantly, in
peripheral blood mononuclear cells (PBMCs) from animals before
vaccination, the percentages of CD4+ and CD8+ cells were not
significantly altered upon PPDB stimulation, indicating that the
animals used in this study were neither previously sensitized nor
infected with M. bovis (Figure 6).
Expression of Cytokines in PBMCs after Vaccination and
Challenge
In order to compare the immune response profile of cattle
vaccinated with the candidate vaccine DleuD BCG-85B with that
of animals vaccinated with BCG and that of the nonvaccinated
group, we measured the cytokine mRNA levels after stimulating
the cells with PPDB at different points after vaccination and
challenge (Figure 7). Values for sequential samples were normal-
ized to values before inoculation for each animal. We assessed the
expression of the proinflammatory cytokines IFN-c and IL-2 and
the anti-inflammatory cytokines IL-4 and IL-10. Given that IL-17
expression has been proposed as a biomarker of cattle protection
against bovine tuberculosis [9], we also quantified the mRNA level
of this cytokine.
At two weeks post-vaccination, only the group vaccinated with
DleuD BCG-85B responded to PPDB stimulation with significant
production of both IFN-c and IL-2 mRNA as compared to the
values for the nonvaccinated group (P,0.05 and P,0.001,
respectively) (Figure 7A and 7B). This high expression of IL-2
mRNA is consistent with the highest frequency of CD4+ and
CD8+ cells expressing the IL-2 receptor (IL-2R) detected at two
weeks post-vaccination in stimulated PBMCs of the DleuD BCG-
85B -vaccinated group (Figure 6). After one month of vaccination,
the expression of IL-2 in PBMCs from both vaccinated groups
increased upon stimulation compared to pre-vaccination, but,
surprisingly, the PBMCs of the nonvaccinated calves also
responded to the PPDB stimulation with IL-2 mRNA expression
at this time point (Figure 7B).
Figure 4. IFN-c production in PPDB-stimulated PBMCs. (A) IFN-c responses in vaccinated and nonvaccinated animals following vaccination
and after challenge. IFN-c production was measured in PPDB-stimulated blood from animals vaccinated with BCG (squares), DleuD BCG-85B
(triangles) or nonvaccinated (circles) at different time points (0, 30 and 60, 120 and 150 days post-vaccination). Animals were infected eight weeks
after vaccination and sacrificed sixteen weeks post-challenge. Arrow indicates the challenge time point. Significance was determined by ANOVA test.
Statistically significantly different to that for the nonvaccinated group, *P,0.05. (B) Correlation between IFN-c production in PPDB-stimulated PBMCs
and disease severity. Results are expressed as IFN-c 40 days post-challenge of individual animals in relation to the corresponding total gross
pathology scores. Solid line indicates linear regression; dashed lines indicate 95% confidence intervals. Values for r2 and p of linear regression analysis
are indicated.
doi:10.1371/journal.pone.0051396.g004
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Stimulation with PPDB induced greater IL-4 gene expression in
animals vaccinated with DleuD BCG-85B than in those vaccinated
with BCG at two weeks post-vaccination (P,0.01) (Figure 7C),
while the expression of IL-10 did not change upon stimulation of
PBMCs from all groups, along the experiment (data not shown).
Importantly, at two and four weeks post-vaccination, PBMCs
obtained from cattle vaccinated with DleuD BCG-85B responded
to PPDB stimulation by expressing 24.2 fold and 7.6 fold,
respectively, more IL-17 mRNA than cells from animals
vaccinated with BCG (P,0.01) (Figure 7D). In fact, stimulation
of cells from the BCG group did not induce IL-17 production at
any point time after vaccination or prior to challenge.
Extending our analysis, we compared IL-17 and IFN-c
expression in relation to the pathology found at post-mortem.
We found a statistically significant negative correlation
(P=0.0178) between IL-17 mRNA expression upon PPDB
stimulation at two weeks post-vaccination and disease severity
(pathology scores) (Figure 8A).
The expression of IFN-c mRNA before challenge showed a
weak not statistically significant correlation with disease severity
(Figure 8B). However, at 40 days post-challenge, the expression of
IFN-c mRNA positively correlated with the presence of lesion in
organs (P=0.0231) (Figure 8C). After challenge, the expression of
all other cytokines upon PPDB stimulation was equivalent in all
groups.
Figure 5. Mean tuberculin skin test responses to PPDB. Animals were vaccinated with BCG (n = 5, squares), DleuD BCG-85B (n = 5, triangles) or
inoculated with PBS (n = 6, circles) and challenged after eight weeks with M. bovis. Values indicate skin thickness at one month post-vaccination and
prior to challenge (A), and three months post-challenge (B). Horizontal lines indicate mean values. Data were analysed using a Mann Whitney
test,*P,0.05, **P,0.005.
doi:10.1371/journal.pone.0051396.g005
Figure 6. Determination of lymphocyte subsets in PPDB-stimulated PBMCs. Percentages of lymphocyte cell subsets CD4+ (A) and CD8+ (B)
expressing CD25 for PPDB stimulated-PBMCs from animals vaccinated with BCG (n = 5, triangles), DleuD BCG-85B (n = 6, circles) or nonvaccinated
(n = 6, squares) at 15, 30 and 60 days after vaccination and 20, 40, 70 and 100 days after challenge. The arrow indicates the challenge time point. Data
were analysed using Mann-Whitney test for comparison between groups. (Statistically significantly different to that for the nonvaccinated group
*P,0.05 and ** P,0.01).
doi:10.1371/journal.pone.0051396.g006
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Figure 7. Relative cytokine gene expression. Gene expression of IFN-c (A), IL-2 (B), IL-4 (C) and IL-17 (D) was measured in PPDB-stimulated
PBMCs from animals vaccinated with BCG (gray), DleuD BCG-85B (white) or nonvaccinated (black) at different time points (15 and 30 days post-
vaccination and 20, 40, 70 and 100 days post-challenge). Transversal line indicates the challenge time point. Relative gene expression was calculated
using the 2-DDCt method with E correction, using gadph mRNA expression as reference gene and the pre-immune condition as the calibrator. Data
were analysed using Mann-Whitney test, statistically significantly different, * P,0.05 and ** P,0.01. The bars indicate the median fold change.
doi:10.1371/journal.pone.0051396.g007
Figure 8. Correlation between IL-17 and IFN-c mRNA expression in PPDB-stimulated PBMCs and disease severity. Results are
expressed as mean increases in IL-17 (A) and IFN-c (B) transcription at 15 days post-vaccination and IFN-c transcription at 40 days post-challenge (C)
of individual animals in relation to the corresponding total gross pathology scores (head lymph nodes, respiratory tract-associated lymph nodes and
lungs). Animals vaccinated with either BCG (squares) or DleuD BCG-85B (triangles) and nonvaccinated (circles) were infected eight weeks after
vaccination and sacrificed sixteen weeks post-challenge. Solid lines in panels A and B indicate linear regression; dashed lines indicate 95% confidence
intervals. Values for r2 and p of linear regression analysis are indicated.
doi:10.1371/journal.pone.0051396.g008
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Discussion
Ag85B has shown to induce protection in both murine and
guinea pig models of infection when expressed in a wide variety of
vectors such as: rBCG, vaccines based on recombinant modified
Vaccinia virus Ankara (MVA) and DNA-based vaccines. Indeed,
MVA-Ag85A is one of the tuberculosis vaccines that are currently
undergoing human clinical trials [15]. A BCG Tice strain
overexpressing Ag85B has been shown to protect guinea pigs
against a M. tuberculosis challenge at higher level than its parental
strain [23,24]. Furthermore, in mice, overexpression of Ag85B,
Ag85A and TB10.4 antigens in a recombinant BCG expressing
perfringolysin O has shown to induce better protection than the
parental BCG [25]. In agreement with these previous findings and
with the immunogenic properties of the Ag85B antigen, in this
study we found that overexpression of the Ag85B antigen in DleuD
BCG Pasteur clearly improved its vaccine efficacy. Indeed,
significant reduction in the histological damage of lungs was
induced in DleuD BCG-85B-vaccinated calves as compared to that
induced by vaccination with BCG. However, in order to confirm
the improved efficacy of this vaccine candidate the study should be
extended to a larger number of calves.
The novelty of this work is the use of auxotrophic complemen-
tation system as selectable marker for stable expression of 85B
antigen in BCG. Although other studies have demonstrated the
use BCG overexpressing 85B, the replicating vectors employed
have antibiotics used as selection markers [24,26,27]. Epissomal
vectors provide higher expression level of heterologous proteins
than integrative vectors, but the stability of multicopy vectors in
BCG depends on selective pressure normally associated with
resistance to antibiotics [28]. This type of selective pressure is lost
during in vivo BCG replication, and results in loss of the epissomal
vector. This might be due to a counter-selective pressure within
the macrophage on strain expressing genes that are not part of the
endogenous mycobacterial chromosome [29]. Me´derle´ et al
demonstrated decreased immune response in recombinant BCG
that rapidly lost the plasmid in vivo compared to stable strains
carrying the heterologous gene integrated into the bacterial
genome [30]. Stable expression of the recombinant Ag85B gene
was obtained in DleuD BCG-85B due to selective pressure
provided by the auxotrophic complementation system [18]. This
is based on the fact that only the complemented DleuD BCG strain
is able to grow inside macrophages [31]. Our system showed
100% stability in vivo for over 30 weeks in mice [18] and for over
20 weeks in hamsters [28], a feature not demonstrated by Badell
et al. [27] when only 54% of in vivo BCG recovered after 58 days
were resistant to antibiotics. An additional advantage is the
absence of an antibiotic resistance gene, a requirement for a live
bacterial vaccine that has been ignored in most experimental
studies with recombinant BCG [20].
Given that there is no doubt about the essential protective role
of CD4+ and CD8+ T cells to control tuberculosis infections, it is
important that any candidate vaccine be capable of stimulating
these cell populations. Therefore, the most effective vaccination
strategies will be those that stimulate CD4+ and CD8+ T cell
responses to produce Th1-associated cytokines. In accordance
with these requirements, the candidate DleuD BCG-85B vaccine
elicited stronger T-cell responses in cattle, with activation of CD4+
and CD8+ following stimulation with the M. bovis specific antigen
PPDB, than that of the nonvaccinated group, while this was not
seen for the BCG-vaccinated group.
Vaccination of cattle with DleuD BCG-85B induced in
stimulated PBMCs, prior to M. bovis challenge, the transcription
of IFN-c, IL-4 and IL-17 mRNAs, while vaccination with BCG
did not. This higher IFN-c production in DleuD BCG-85B
vaccinated cattle as compared to BCG-vaccinated and nonvacci-
nated groups was also detected in whole-blood PPD-B stimulated
samples. However, the overall level of IFN-c detected in individual
animals before challenge did not correlate with protective efficacy,
which is consistent with previous TB vaccine studies in cattle
(reviewed by Buddle et al. [32]). Altogether these results indicate
that the use of IFN-c production as predictor of cattle protection
against M. bovis challenge deserves more investigation. The higher
IL-4 mRNA expression induced in the DleuD BCG-85B -
vaccinated group may suggest that anti-inflammatory responses
in animals inoculated with this candidate vaccine were generated
to attenuate the adverse effect of an exacerbated inflammation of
the host tissues driven by the highly expressed IFN-c.
Importantly, we found a negative correlation between IL-17
expression after vaccination and the disease severity observed post-
mortem. These results confirm the findings of Vordermeier et al.
[10], who reported that high IL-17 responses in vaccinated cattle
prior to challenge correlates with protection against M. bovis, and
validate the use of this cytokine expression as a predictor or
surrogate of protection, which would be very useful to estimate the
vaccine efficacy without the need to infect animals with M. bovis.
It has been reported that in cattle experimentally infected with
M. bovis the expression of IFN-c, TNF-a, iNOS and IL-4 by
PBMCs increase in response to infection, andthat animals with
high pathology express more IFN-c, TNF-a, iNOS and IL-4 than
animals with low pathology [33]. However, the source of IFN-c
production seems to have relevance in its association with
pathology since previous studies in cattle have only found
significant correlations between pathology and post-challenge
IFN-c secretion when PBMC cultures were stimulated with
ESAT-6/CFP10 but not when these cultures were stimulated
with PPDB [3,34]. In the current study, we found positive
correlation between the expression of IFN-c in PPDB-stimulated
PBMCs and the extent of tissue damage, at 40 days post-challenge,
at both transcriptional and translational levels, but, after 40 days
post-challenge, this positive correlation was no longer detected.
These results suggest that PPD-B specific IFN-c secretion from
PBMC cultures is a marker of diseases severity, although the
inclusion of M. bovis specific antigen, such as ESAT-6/CFP-10,
would improve the power of this disease predictor.
No correlation was observed between IL-4 mRNA expression
and disease severity (data not shown). In fact, the expression of IL-
4 mRNA was practically unchanged after M. bovis challenge in all
cattle groups. Similarly, no significant changes were detected in
the expression level of IL-10 mRNA upon M. bovis infection or
vaccination for any cattle group. It has been proposed that as the
tuberculosis disease progresses, there is a shift from Th1 to Th2
responses. Although our results suggest that the immune profile
did not shift during the experimental time of this study, we cannot
rule out the possibility that it may occur later during the infection.
Taken together, these data indicate that, in cattle, DleuD BCG-
85B induces a strong Th1 response that is maintained for at least
60 days. Nevertheless, it will be of interest in further studies to
determine which kind of T cell subpopulation produces each
cytokine and identify those T cell populations that simultaneously
produce more than one cytokine, as recent studies in mice have
associated vaccine success with the increased presence of so-called
polyfunctional T cells that produce, for example, IL-2, IFN-c, and
TNF-a [35–37]. The lack of commercial reagents to detect IL-2
and some other cytokines has been an important limitation toward
the study of polyfunctional CD4 T cells in cattle as to detect
intracellular cytokines by flow cytometry in cattle. However, an
antibody that recognizes biologically active bovine IL-2 has been
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recently identified [38]; therefore the availability of this new tool
could allow a better understanding of the complex T cell-mediated
immune responses in cattle. It would be also important to establish
the frequencies of memory T cell subsets that proliferate in
response to specific stimulation in DleuD BCG-85B vaccinated
animals. Memory T cells can be divided in central memory T cells
(TCM) and effector memory T cells (TEM) according to their
homing characteristics and effector function, and increasing
evidence indicates that TCM have a greater capacity than TEM
in mediating protection because of their high proliferative
responses [39]. This analysis would allow us to dissect the T cell
responses induced post-challenge that may explain the lack of
correlation observed when the level of protection conferred by
vaccination is compared to T cell frequencies, in total, without
discriminating T cell subsets.
Altogether these results demonstrate that vaccination of cattle
with DleuD BCG-85B induces protective immune responses
against TB. However, some immunological parameters, such as
cytokine expression and T cell proliferation, indicate that this
protective immune response is only significantly superior to that
induced by conventional BCG, early after vaccination. Therefore,
we speculate that use of a prime boost scheme, in which viral
vectors expressing antigen 85B boosts the anti-85B response
induced by DleuD BCG-85B vaccine, will significantly improve the
efficacy of the candidate here described. The study used out-bred
animals as this is relevant to the use of TB vaccines in the field.
Although there have been some studies investigating natural
resistance to TB in cattle there have not been reports on the
influence of genetic background of cattle to their response to
vaccination against TB.
It has been clearly demonstrated that the specificity of the
tuberculin skin test, used for the diagnosis of bTB, is compromised
by vaccination with vaccines derived from BCG [40]. In fact, we
observed significant skin test reactivity one month post-vaccination
of cattle with either BCG or DleuD BCG-85B. Importantly, this
positive reactivity in the animals vaccinated with DleuD BCG-85B
decreased three months post challenge to values significantly lower
than that of the nonvaccinated group, although no correlation was
found between severity disease and skin test reactivity in all
challenged animals.
The development of diagnostic tests that allow differentiating
vaccinated from infected animals (DIVA test) is a prerequisite to
use BCG-based vaccination against tuberculosis in cattle. Recent-
ly, Vordermeier et al. [41] defined combinations of M. tuberculosis
complex antigens for DIVA diagnosis, which included ESAT6 and
CFP10 antigens. Later on, Flores-Villalva et al. [42] assessed the
effectiveness of an ESAT6-CPP10 antigen cocktail as an intra-
dermal diagnostic test in field assays and found that this antigen
combination allows identification of an important proportion of
animals that PPDB was not able to recognize, especially in low-
prevalence herds. The fact that ESAT6 and CFP10 are absent
from BCG, and in turn from the DleuD BCG-85B candidate
vaccine, allows the use of these both immunodominant antigens as
DIVA reagents (either in an intradermal test or in the Bovigam
IFN-c assay) in combination with the DleuD BCG-85B vaccine, as
part of a program to control bTB.
Given that the immune responses between bovines and humans
have been considered a determinant issue in the development of
diagnostic tools and vaccines both for human and bovine
tuberculosis [43], the results presented here make this recombinant
BCG an attractive candidate vaccine to be tested against both
bovine and human tuberculosis.
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